|
Biopharmaceutical company Vectura Group strives to be a breath of fresh air to patients with respiratory ailments. The company develops inhalable drug therapies and inhaler devices for the treatment of asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). It also makes inhalable products for a select few non-respiratory diseases as well. Vectura's pipeline includes about 10 therapies that are in middle and late stage development, but the company also earns royalties off of drug products that it markets through licensing agreements with pharmaceutical companies like Baxter, UCB, and Mylan Inc. Its products are distributed primarily in the US and Europe.
|
| | | Contact Information | |
Address: |
1 Prospect West
Chippenham, Wiltshire SN14 6FH, United Kingdom
| | Phone: | +44-01249 667700 | | Fax: | +44-01249 667701 |
|
| Financial
Highlights | | Fiscal Year End: | March | | Revenue (2008): | 49.50 M | | Employees (2008): | 110 |
|
|
Key People
| | • |
Chairman:
John P. (Jack) Cashman
| | • |
CEO and Director:
Christopher (Chris) Blackwell
| | • |
CFO, Secretary, and Director:
Anne P. Hyland
|
|
|
